

Selected Clinical Research Protocols Relating to Melanoma

More information on the trials listed below is available at PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at www.cancer.gov/clinicaltrials. A searchable Web site developed by the National Library of Medicine is also available at www.clinicaltrials.gov.

Phase III

Randomized Adjuvant Study of High-Dose Interferon Alfa-2b Therapy in Patients With Stage II or III Melanoma

NCT00003641

Study of MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma

NCT00094653

Randomized Study of Carboplatin and Paclitaxel With Versus Without Sorafenib in Patients With Unresectable Stage III or Stage IV Melanoma

NCT00110019

Study of PegIntron vs IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)

NCT00221702

Phase III/I

Study of the Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2

NCT00279058

Study of Sorafenib and Temsirolimus in Patients With Metastatic, Recurrent, or Unresectable Melanoma

NCT00349206

Dose Escalation Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

NCT00421811

Phase I

Study of Sorafenib Tosylate in Combination With Regional Melphalan Via Normothermic Isolated Limb Infusion in Patients With Stage IIIB or IIIC Intransit Extremity Melanoma

NCT00565968

The following trials are currently being conducted at Moffitt Cancer Center. For additional information about these trials, please call Cheryl Maker in the Clinical Research Department at (813) 745-4106 or e-mail cheryl.maker@moffitt.org.

Phase III

Randomized Study of Complete Lymph Node Dissection Versus Observation in Patients With Localized Cutaneous Melanoma and Sentinel Node Metastasis Who Have Undergone Sentinel Lymphadenectomy

MCC-14120, NCT00389571

Randomized Study of Percutaneous Isolated Hepatic Arterial Perfusion With Melphalan With Subsequent Venous Hemofiltration Versus Best Alternative Standard Treatment in Patients With Unresectable Liver Metastases Secondary to Ocular or Cutaneous Melanoma

MCC-15316, NCT00324727

Phase II

Compassionate Use Trial for Unresectable Melanoma With Ipilimumab

MCC-15283, NCT00495066

A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma (BEAM)

MCC-15179, NCT00434252

Randomized Study of Lovastatin in Patients With a High-Risk for Recurrent Melanoma

MCC-15168, NCT00462280

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

MCC-15257, NCT00243191

Trial of ZK-EPO (ZK 219477) in Metastatic Melanoma

MCC-14965, NCT00598507

Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III

or IV Melanoma

MCC-15241, NCT00084656

A Rollover Protocol for Patients Who Received CP-675,206 in Other Protocols

MCC-15014, NCT00378482

Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

MCC-15458, NCT00424515

Phase I/II

Randomized Study of Vaccination Comprising MART-1/gp100/Tyrosinase/NY-ESO-1/MAGE-3 Peptide-Pulsed Dendritic Cells Matured Using Cytokines in Combination With Autologous Lymphocyte Infusion With or Without Fludarabine in Patients With Chemotherapy-Naïve Metastatic Melanoma

MCC-13649, NCT00313508

Study of Dasatinib and Dacarbazine

MCC-15256, NCT00597038

Phase I

Safety and Immune Response to a Multi-Component Immune-Based Therapy (MKC1106-PP) for Patients With Advanced Cancer

MCC-15222, NCT00423254

Oncovir Poly ICLC and Tyrosinase/gp100 MART-1 Peptides Emulsified in Resected Stage III or Stage IV Melanoma

MCC-15383